Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for ...

Azitra (NYSE American: AZTR) on Wednesday it has been granted a U.S. patent covering its lead product candidate ATR-12, an engineered microbial therapy under development for Netherton syndrome. The ...

(“AV”) (NASDAQ: AVAV) today announced that it has been awarded a prototype agreement from the U.S. Army for the Low-Altitude ...

DrugSorb-ATR’s regulatory pathway in the U.S. was clarified after an initial denial, with the FDA identifying only "remaining open items" needed for resubmission and confirming device safety. PuriFi’s ...

Good afternoon, ladies and gentlemen, and welcome to the Cytosorbents Fourth Quarter and 2025 Full Year Earnings Conference Call. [Operator Instructions] This call is being recorded on Wednesday, ...

ATR is planning to turn its attention to main landing gear maintenance as part of its in-service improvement program, which was formally launched in 2025. Speaking at the release of ATR’s 2025 results ...

ATR reported €1.2 billion in revenue for 2025, right as the turboprop aircraft maker is gearing up to ramp up production in 2026. At a press conference held at the company’s premises in Toulouse, ...

(RTTNews) - Aprea Therapeutics, Inc. (APRE) has broadened its global intellectual property estate with newly granted patents in Australia and Japan, reinforcing long-term protection for its WEE1 and ...

Monday - Friday, 11:00 - 12:00 SIN/HK | 0500 - 06:00 CET Nathalie Tarnaud Laude, CEO of ATR, says the Indian aviation market has big potential and that the company is working closely with airline ...

Private charter carrier JSX to fly to Las Vegas and Scottsdale from history Santa Monica Airport, buy up to 30 of the populaar ATR turboprops for use from smaller airports. An ATR turboprop in JSX ...

The Evo SL has become a tremendous hit for Adidas, widely praised by runners and becoming the brand’s top-selling model in the category. Now, with winter conditions setting in, a reinforced version of ...

Variational AI’s Enki™ generative AI platform designed novel ATR/mTOR dual inhibitors with brain penetrance and activity in PTEN-deficient tumor models VANCOUVER, British Columbia, Nov. 24, 2025 ...